Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Pharmacist Guide to Psilocybin and Psychedelic-Assisted Psychotherapy.American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists · 2026-11-06Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-11-05Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderClinicalTrials.gov · 2026-11-05A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-10-29Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among VeteransClinicalTrials.gov · 2026-10-26A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-10-23A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-10-21Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe AnxietyDrugs and Drug Candidates · 2026-08-12A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-13PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10Psilocybin-Enhanced Psychotherapy for Methamphetamine Use DisorderClinicalTrials.gov · 2026-04-22Effects of Serotonergic Psychedelics on Synaptic Function and NeuroplasticityOPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg · 2025-12-31The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationClinicalTrials.gov · 2025-12-24A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic CancerClinicalTrials.gov · 2025-11-05A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic CancerClinicalTrials.gov · 2025-10-14Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.Frontiers in systems neuroscience · 2025-01-01Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyClinicalTrials.gov · 2024-12-04Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.The Cochrane database of systematic reviews · 2024-09-12An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)ClinicalTrials.gov · 2024-08-09Repeat Dosing of Psilocybin in Headache DisordersClinicalTrials.gov · 2024-02-09Safety and Efficacy of Psilocybin for the Treatment of Headache DisordersClinicalTrials.gov · 2023-12-15Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study IIClinicalTrials.gov · 2023-10-12Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study IClinicalTrials.gov · 2023-10-12The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-24NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.ClinicalTrials.gov · 2022-11-16The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.ClinicalTrials.gov · 2022-10-25Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a WorkshopNational Academies Press (US), Washington (DC) · 2022-09-01Addressing the Implicit Impacts of Sexual Trauma: An Exploration of Somatic Experiencing as an Adjunct to Psilocybin-Assisted TherapyNational University System Repository (National University System) · 2021-04-30Is Psilocybin an Effective Treatment to Reduce Depression and Anxiety in Cancer Patients with a Diagnosis of an Anxiety Disorder, Mood Disorder, And/Or Stress Disorder?Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine) · 2020-01-01Are psychedelics effective in treating anxiety associated with a lifethreatening diseaseDigital Commons - PCOM (Philadelphia College of Osteopathic Medicine) · 2018-01-01Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term MeditatorsClinicalTrials.gov · 2014-05-20